AeonClad Coatings seeks collaborative partners in medical devices, drug discovery, and industrial processing interested in unique applications of plasma deposition for high-tech, coated surfaces. Applications may include coating of stents, catheters, functional binding arrays, and other industrial coatings.

If you are interested in exploring a partnership with AeonClad Coatings, email info@aeonclad.com

Market Opportunity
The global market for medical device coating and surface treatment products and processes is expected to exceed $5 billion by 2010*, with demand being driven by cardiovascular medicine, dentistry, general and plastic surgery, general hospital settings, neurology, ophthalmology, orthopedics and radiology.

The drug delivery also presents a significant opportunity for AeonClad Coatings. This global market is estimated to be $36 billion (2006) and growing at 10% each year, driven by an aging population, shrinking drug pipelines, and patent expiry.

*Source: Kalorama

AeonClad Coatings’ proprietary pulsed plasma deposition technology enables the company to take advantage of these market opportunities by delivering the highly controllable, reproducible, customizable surface treatments necessary for the industry’s growth.

Business Synergies
AeonClad Coatings is funded and managed by Emergent Technologies, Inc. (ETI), a venture capital firm with more than a dozen portfolio companies and technologies. ETI seeks scientific and business synergies within its portfolio of companies and partners, leveraging combined expertise to maximize opportunities for successful commercialization.

ETI has succeeded not only in gaining access to significant capital, but also in creating an efficient corporate structure that reduces costs of each company in our portfolio, leverages existing relationships and expertise, and successfully processes multiple opportunities without duplicating overhead and costs for each new endeavor.